Coagulation factor VII (FVII) is a vitamin K-dependent serine protease that has a key role in the initiation of the coagulation cascade. This factor circulates in the blood at a concentration of 0.5 μg/mL and its severe reduction leads to rare autosomal recessive bleeding disorder, FVII deficiency [1,2]. The
The most common FVII deficiency symptoms consist of soft tissue, mucocutaneous, joint and gastrointestinal hemorrhage. The hereditary form of the disease shows considerable phenotypic heterogeneity ranging from lethal to mild or even asymptomatic types. As a result, prevalence and incidence of FVII deficiency is not entirely determined [7]. Studies show that the incidence of clinically significant FVII deficiencies is estimated to be 1/500,000 [8]. However, the disease is more frequent where consanguineous marriages are commonplace [9]. The severity of hemorrhagic symptoms is not directly related to the level of plasma FVII coagulant activity [2,10]. In a study on 717 patients, Herrmann
We here report on the characterization of the mutations in eight patients from eight unrelated families in Iran. We also intended to elucidate the effect of each mutation on their corresponding mRNA expression.
This study was approved by the ethics committee of the Iran National Science Foundation (INSF). Eight FVII deficiency patients participated in this study after we obtained written informed consent. They were selected from eight unrelated families living in different parts of Tehran Province, Iran. The patients were referred to the Clinic of Hematology and Oncology, Imam Khomeini Hospital in Tehran, Iran. All of them were evaluated by a hematologist for clinical manifestation and tested for bleeding abnormalities and coagulation factor levels.
For DNA and RNA extraction, 5 mL of peripheral blood was collected from each patient in EDTA-containing vacutainers. Each sample was divided into two aliquots, one to be used for peripheral blood mononuclear cells (PBMCs) and RNA isolation and the other for DNA extraction. In order to separate PBMCs, the blood samples were centrifuged at 150 g for 20 min.and the plasma content (upper phase) was removed. The cells in the lower phase were resuspended (1:2 V/V) with phosphate-buffered saline (PBS), overlaid on Ficoll-Plaque™ (Sigma-Aldrich Co. Ltd., Gillingham, Dorset, UK) and centrifuged at 400 g for 30 min. at room temperature. The PBMC layer were collected and stored at –80 °C until used for RNA isolation.
Genomic DNA was extracted from the whole blood samples using a salting-out method. The concentration and purity of the isolated DNA were determined by a spectrophotometer (Nanophotometer™; Implen GmbH, München, Germany). High quality DNA (A260/280≥1.8) was selected and kept at –20 °C.
The primers were designed to amplify all
Characteristics of the primer sets used for the polymerase chain reaction assay. F: forward; R: reverse.Oligo Primers Sequences (5’>3’) Tm Amplicon (bp) F71aF GAA CTT TGC CCG TCA GTC CC F71aR CCG CCA GAA AAC CCT CCT G 61 258 F71bF GAC AGT GCC TGG GAT GTG G F71bR GAG CGG TCA CTT CCT CTC GA 60 293 F72F GGG AAG GAT GGG CGA CGG F72R CCA GGA AAG CGG AGT CAC CC 62 534 F734F TGT CCA GTG CTT ACC GTT GG F734R AAT TTC CAA CTG GGG CTG AG 59 419 F75F GAT CAG TCC ACG GAG CAG G F75R GTA GAT GTG AAG CCA CTC CC 58 408 F76F CTG AAT CTT TCC TAG TGG CAC G F76R CAA AAG GCT TCA AGA CCC TCA G 59 235 F77F AGC AAT GTG ACT TCC ACA CC F77R AGC CCC CAG TCT TTT ATC GT 58 543 F78aF CCC AGA CCC CAG ATT CAC CC F78aR GCC TCC ACT GTC CCC CTT G 62 633 F78bF AGT CAC GGA AGG TGG GAG AC F78bR GGG ATT TGG TGC CAG GAC AG 61 349
Polymerase chain reactions included 0.4 μM of each primer and 50 ng of genomic DNA in 2×PCR master mix (Ampliqon; Pishgam Biotech, Tehran, Iran ) containing 0.2 units/μL Ampliqon Taq DNA polymerase and 2.5mM MgCl2. The PCR amplification involved an initial denaturation step for 5 min. at 94 °C and 30 cycles of 30 seconds at 94 °C, primer annealing temperature for 30 seconds and 72 °C for 1 min., followed by a final extension step at 72 °C for 5 min. Amplified fragments were sequenced and the data were analyzed using Chromas software (
RNA was extracted from PBMC pellets using NucleoSpin® RNA Blood kit (Macherey-Nagel; Bahar-Tashkhis, Tehran, Iran) as recommended by the manufacturer. The concentration and purity of the purified RNA were determined by spectrophotometry and gel electrophoresis. High quality RNA (A260/280≥1.8) was selected and kept at –80 °C until used for cDNA synthesis. Up to 1 μg RNA was converted to cDNA using RevertAid First Strand cDNA synthesis kit (Thermo Scientific; NedayeFan Company, Tehran, Iran) according to the manufacturer’s instructions. To verify the integrity of the cDNA, a RT-PCR experiment was performed using
The purified cDNA was subjected to amplification and sequencing. The primers were designed by Oligo explorer software (V 1.2) and specified using the BLAST website as described in Table 2. Reverse transcription-polymerase chain reactions were performed in a final volume of 25 μL containing 2 μL of cDNA, 1 μL of each primer in 2×PCR master mix. The RT-PCR amplification program started with a single denaturation step at 94 °C for 5 min. and followed by 30 cycles of 30 seconds at 94 °C, primer annealing temperature for 30 seconds and 72 °C for 1 min., followed by a final extension step at 72 °C for 5 min. Amplified fragments were analyzed by DNA sequencing to determine the proportion of mutation-containing transcript. Relative allele-specific mRNA quantitation by DNA sequencing was carried out as described previously [14,15].
Characteristics of the primer sets used for the reverse transcription-polymerase chain reaction assay. F: forward; R: reverse.Oligo Primers Sequences (5’>3’) Tm Amplicon (bp) F7cD1F CAA CAG GCA GGG GCA GCA C F7cD1R TCG TGG CAC CGA CAG GAG C 63 303 F7cD2F TGT GTG AAC GAG AAC GGC G F7cD2R ACC TTC CGT GAC TGC TGC 60 680 F7cD3F ATG TGG TGC CCC TCT GCC F7cD3R TGT CTC TGT CTC CCT CCC CA 62 591
Patient characteristics, symptoms and plasma FVII coagulation activity (FVII:C). NA: not applicable.Patient Sex-Age Consanguinity FVII:C (IU/dL) Hemorrhagic Symptoms Patient 1 M-22 no 18.0% gastrointestinal bleeding, epistaxis, oral cavity bleeding, cutaneous symptoms Patient 2 M-34 yes 7.0% hemarthrosis, epistaxis, oral cavity bleeding, cutaneous symptoms Patient 3 F-32 no 33.0% menorrhagia, epistaxis, oral cavity bleeding, cutaneous symptoms Patient 4 M-54 no 29.0% asymptomatic Patient 5 M-20 NA 2.0% cutaneous symptoms, epistaxis, oral cavity bleeding Patient 6 M-67 yes 16.0% epistaxis, oral cavity bleeding, cutaneous symptoms Patient 7 M-26 no <1.0% hemathrosis, epistaxis, oral cavity bleeding, cutaneous symptoms Patient 8 M-31 no 25.0% gastrointestinal bleeding, epistaxis, oral cavity bleeding, cutaneous symptoms
Eight different
The Patient Exon Nucleotide Change Amino Acid Change Genotype MutationTaster2 Prediction a Patient 1 8 g.10648C>T (g.12728C>T) (GCG>G7G) A244V (A282V) heterozygote disease causing score: 64 Patient 2 8 g.10824C>A (g.12904C>A) (CCC>ACC) P303V (P341T) homozygote disease causing score: 38 Patient 3 8 g.10648C>T (g.12728C>T) (GCG>G7G) A244V (A282V) heterozygote disease causing score: 64 Patient 4 1a g.64G>A (g.115G>A) (GTC>ATC) V(–39)I (V22I) heterozygote disease causing score: 29 Patient 5 5 g.7807G>C (g.9891G>C) (TGT>TCT) C91S (C129S) homozygote disease causing score: 112 Patient 6 8 g.10828G>A (g.12908G>A) (CGG>CAG) R304Q (R342Q) homozygote disease causing score: 43 Patient 7 8 g.10763C>G (g.12843C>G) (AGC>AGG) S282R (S320R) compound disease causing score: 110 8 g.10960A>G (g.13040A>G) (CAT>CGT) H348R (H386R) heterozygote disease causing score: 29 Patient 8 8 g.10828G>A (g.12908G>A) (CGG>CAG) R304Q (R342Q) compound disease causing score: 43 Intron 7 g.9733A>G (IVS7+7A>G) – heterozygote disease causing score: –
Despite the low level of
Direct sequencing of PBMC-derived cDNA for A244V, S282K, H348Q and R304Q mutations revealed equal expression of wild-type and mutant allele transcripts. These variants were detected in the compound heterozygous and heterozygous patients. In addition, the cDNA analysis in homozygous patients indicated that mutationharboring transcripts,
Identification of underlying gene alterations and their expression changes can be a prerequisite for the proper evaluation and management of the FVII deficiency. In our study, we found three homozygous patients, two of them had consanguineous parents, while the third patient was an adopted child with no available records regarding his family of origin. We also characterized molecular changes in two compound heterozygous and three heterozygous patients.
Mutation detection in patient 2 revealed the 10824C>A homozygous substitution that causes the P303T defect in FVII protein. This mutation was previously detected in an Iranian patient [16]. It has been shown that residues P303, L305 and M306 are involved in tissue factor (TF) binding [17].
Another homozygous mutation was found in patient 5, C91S that was previously identified in an English patient [18]. Since C91 is engaged in disulfide bond formation, this mutation could be a basis of severe dysfunction of the enzyme. However, patient 5 did not exhibit severe complications such as hemarthrosis or gastrointestinal bleeding. Further studies are needed to explore the role played by different factors in determining the phenotypic variation of each mutation.
The highest prothrombin time (PT) and partial thromboplastin time (PTT) (34 and 44 min., respectively) were found in patient 6 homozygous for a rather frequent gene defect, the R304Q mutation. The R304Q mutation was first found in a heterozygous state in a patient with no clinical bleeding tendency by O’Brien
Another compound heterozygous case in our study was patient 7. Both mutations in this patient were located on exon 8, S282R and H348R. The mutation S282R was reported previously by Peyvandi
As stated earlier, some individuals with heterozygous
The only asymptomatic patient that we tested was patient 4, a 54-year-old man diagnosed on pre anesthesia blood analysis. Further molecular investigation revealed a heterozygous genotype with the 64G>A missense mutation. This mutation was previously reported in a Turkish family [26]. The 64G>A is located at the last nucleotide of exon 1a and is known as V(–39)I or V(–17)I. As reported by Wulff and Herrmann [26], the homozygous form of this mutation could cause the severe manifestations such as postpartal (after birth) cephalic hematomas. It should be noted that in communities with a preference for consanguineous marriages, mutation detection of asymptomatic or mild cases could be of great importance in genetic counseling. The cDNA sequencing revealed no expression of mRNA carrying the 64A allele. This may be due to inefficient splicing or mRNA decay. However, the
In conclusion, in the present study, we found eight different